Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials-Reference-Cited by-同舟云学术

Incorporating Parp-inhibitors in Primary and Recurrent Ovarian Cancer: A Meta-analysis of 12 phase II/III randomized controlled trials

Published:2020-07 Issue: Volume:87 Page:102040
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Ruscito Ilary,Bellati Filippo,Ray-Coquard Isabelle,Mirza Mansoor Raza,du Bois Andreas,Gasparri Maria Luisa,Costanzi Flavia,De Marco Maria Paola,Nuti Marianna,Caserta Donatella,Pignata Sandro,Dorigo Oliver,Sehouli Jalid,Braicu Elena Ioana

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference34 articles.

1. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer;duBois;J Natl Cancer Inst,2003

2. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study;Ozols;J Clin Oncol,2003

3. Incorporation of bevacizumab in the primary treatment of ovarian cancer;Burger;N Engl J Med,2011

4. A phase 3 trial of bevacizumab in ovarian cancer;Perren;N Engl J Med,2011

5. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer;Moore;N Engl J Med,2018

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach;Nature Reviews Clinical Oncology;2024-09-04

2. Safety assessments and clinical features of PARP inhibitors from real-world data of Japanese patients with ovarian cancer;Scientific Reports;2024-06-01

3. Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-02

4. Comparison of poly (ADP-ribose) polymerase inhibitors (PARPis) as maintenance therapy for newly-diagnosed and platinum-sensitive recurrent ovarian cancer with BRCA mutational status: a systematic review and network meta-analysis;Expert Review of Anticancer Therapy;2024-01-04

5. PARP inhibitors in newly diagnosed or recurrent ovarian cancer maintenance therapy: evidence of efficacy and safety from randomized controlled trials;Biomedical Research and Therapy;2023-12-31